Results 131 to 140 of about 36,985 (244)
Meta‐Analysis: Prevalence and Incidence of Gastroparesis Following Lung or Heart Transplantation
Alimentary Pharmacology &Therapeutics, Volume 63, Issue 10, Page 1348-1359, May 2026.Gastroparesis occurs in nearly one‐third of lung and heart‐lung transplant recipients (pooled prevalence 31.9%; incidence 25.7%), driven by surgical complexity, perioperative opioid exposure, and diagnostic criteria. Standardized gastric emptying assessment and multidisciplinary management, including opioid minimization, immunosuppressant optimization,
Mohamed H. Eldesouki +9 more
wiley +1 more source
Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review
British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos +16 more
wiley +1 more source
Cell Proliferation, Volume 59, Issue 5, May 2026.Summary of the functions of the NTRK2 receptor during lung injury and regeneration. Our recent work using both human organoid and mouse disease models highlights the non‐conventional role of NTRK2 isoforms in regulating pulmonary vasculature and alveolar regeneration during bronchopulmonary dysplasia.
Gan Zhou, Cheng Tan, Yifei Miao
wiley +1 more source
Liver International, Volume 46, Issue 5, May 2026.ABSTRACT Strong non‐invasive tests (NITs) are needed to predict decompensation in patients with compensated advanced chronic liver disease (cACLD) and improve personalized patient care. We conducted a comprehensive review of the studies evaluating the effectiveness of NITs in predicting decompensation or liver‐related death in patients with cACLD.
Audrey Payancé +5 more
wiley +1 more source
Deficiência de alfa-1-antitripsina na doença pulmonar obstrutiva crónica [PDF]
, 2009 Introdução – A deficiência de alfa-1-antitripsina é uma das alterações genéticas graves encontradas por todo o mundo. Porém, permanece subdiagnosticada, apesar da forte predisposição à doença pulmonar obstrutiva crónica que condiciona.
Cardoso, Patrícia Neves
core
Albumin Restores Endothelial Cell Mitochondrial Morphology in Patients With Decompensated Cirrhosis
Liver International, Volume 46, Issue 5, May 2026.ABSTRACT Background & Aims Endothelial cell (EC) activation is a critical driver of disease progression in cirrhosis, contributing to acute decompensation (AD) and acute‐on‐chronic liver failure (ACLF). Although human albumin administration improves EC function in cirrhotic patients with hypoalbuminemia, its direct effects on ECs remain unclear.
Susan E. Fischer +5 more
wiley +1 more source
Journal of Inflammation Research, 2018 Danielle M Dunlea, Laura T Fee, Thomas McEnery, Noel G McElvaney, Emer P Reeves Irish Centre for Genetic Lung Disease, Department of Medicine, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland Abstract: Alpha-1 antitrypsin (AAT) is
Dunlea DM +4 more
doaj
The FASEB Journal, Volume 40, Issue 8, 30 April 2026.Serum SERPINA3 levels were higher in BOS compared to non‐BOS patients. OPG and SERPINA3 positive cells colocalized with tryptase positive mast cells in airways from BOS lung tissue. OPG and SERPINA3 staining positively correlated in partially and completely obstructed airways.
Yanzhe Liu +8 more
wiley +1 more source
Portacaval shunt in three children with alpha‐1‐antitrypsin deficiency and cirrhosis: 9 to 12⅓ years later [PDF]
, 1990 Busuttil, RW +3 more
core +1 more source